<DOC>
	<DOCNO>NCT02049593</DOCNO>
	<brief_summary>This phase I trial study side effect best dose poly ( adenosine diphosphate [ ADP ] -ribose ) polymerase ( PARP ) inhibitor BMN-673 give together temozolomide irinotecan hydrochloride treat patient locally advance metastatic solid tumor . PARP inhibitor BMN-673 may stop growth tumor cell block enzymes need cell growth may help temozolomide irinotecan hydrochloride work well make tumor cell sensitive drug . Drugs use chemotherapy , temozolomide irinotecan hydrochloride , work different way stop growth tumor cell , either kill cell stop divide . Giving PARP inhibitor BMN-673 temozolomide irinotecan hydrochloride may effective treatment patient advance solid tumor .</brief_summary>
	<brief_title>PARP Inhibitor BMN-673 Temozolomide Irinotecan Hydrochloride Treating Patients With Locally Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess safety tolerability estimate maximum tolerate dose ( MTD ) follow combination participant advance solid tumor : Arm A : BMN 673 ( PARP inhibitor BMN-673 ) temozolomide ; Arm B : BMN 673 irinotecan ( irinotecan hydrochloride ) . SECONDARY OBJECTIVES : I . To evaluate pharmacokinetics BMN 673 , temozolomide , irinotecan BMN 673 give combination temozolomide ( Arm A ) irinotecan ( Arm B ) . To assess effect temozolomide irinotecan Arms A B respectively pharmacokinetics BMN 673 . II . To evaluate biomarkers correlate effect BMN 673 combination temozolomide irinotecan . III . To document anti-tumor activity . OUTLINE : This dose-escalation study PARP inhibitor BMN-673 . Patients assign 1 2 treatment arm . ARM A : Patients receive PARP inhibitor BMN-673 orally ( PO ) daily ( QD ) day 1-28 temozolomide PO daily days1-5 . Courses repeat every 28 day absence disease progression unacceptable toxicity . ARM B : Patients receive PARP inhibitor BNM-673 Arm A irinotecan hydrochloride intravenously ( IV ) day 1 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 12 month .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Talazoparib</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Poly ( ADP-ribose ) Polymerase Inhibitors</mesh_term>
	<criteria>Histologically cytologically document , unresectable , locally advanced metastatic solid tumor standard therapy recognize standard therapy fail Measurable disease define Response Evaluation Criteria Solid Tumors version 1.1 ( RECIST , v1.1 ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Serum aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) = &lt; 2.5 x upper limit normal ( ULN ) ; liver function abnormality due hepatic metastasis , AST ALT may = &lt; 5 x ULN Total serum bilirubin = &lt; 1.5 x ULN Calculated creatinine clearance &gt; = 40 ml/min ; per CockcroftGault formula Hemoglobin &gt; = 9.0 g/dL Absolute neutrophil count ( ANC ) &gt; = 1500/mm^3 Platelet count &gt; = 100,000/mm^3 Able take oral medication Willing able provide write , sign informed consent nature study explain , prior researchrelated procedure Sexually active patient must willing use acceptable method contraception double barrier contraception treatment 30 day last dose BMN 673 Females childbearing potential must negative serum pregnancy test screening Has recover ( recovery define National Cancer Institute [ NCI ] Common Terminology Criteria Adverse Events [ CTCAE version ( v ) 4.03 ] grade = &lt; 1 ) acute toxicity previous therapy , except treatmentrelated alopecia laboratory abnormality otherwise meet inclusion requirement state inclusion criterion Prior treatment PARP inhibitor Prior allergic reaction severe intolerance either irinotecan temozolomide History central nervous system ( CNS ) metastasis untreated stable Any antitumor systemic cytotoxic therapy within 28 day prior enrollment ( 6 week nitrosoureas mitomycinC ) ; prior highdose chemotherapy bone marrow stem cell transplant exclude Is know human immunodeficiency virus ( HIV ) active hepatitis C virus ( HCV ) , active hepatitis B virus ( HBV ) Has major surgery within 28 day prior enrollment Active gastrointestinal tract disease malabsorption syndrome Requirement IV alimentation Uncontrolled inflammatory bowel disease ( e.g. , Crohn 's disease , ulcerative colitis ) Symptomatic congestive heart failure ( New York Heart Association &gt; class II ) , unstable angina , unstable cardiac arrhythmia require medication ( atrial fibrillation permit ) Use investigational product investigational medical device within 28 day prior enrollment Concurrent disease condition would interfere study participation safety , : Active , clinically significant infection require use parenteral antimicrobial agent , grade &gt; 2 NCI CTCAE ( v 4.03 ) within 14 day prior enrollment Clinically significant bleeding diathesis coagulopathy , include know platelet function disorder Nonhealing wound , ulcer , bone fracture Bone marrow disorder include myelodysplasia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>protocol specific</keyword>
</DOC>